TCM
DAWN

TimesSquare Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

TimesSquare Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,710,926
Closed -$21.7M – 147
2024
Q4 		$21.7M Sell
1,710,926
-116,769
-6% -$1.62M 0.32% 115
2024
Q3 		$25.5M Buy
1,827,695
+139,160
+8% +$1.99M 0.38% 104
2024
Q2 		$23.3M Buy
1,688,535
+53,390
+3% +$781K 0.37% 105
2024
Q1 		$27M Sell
1,635,145
-30,920
-2% -$463K 0.39% 99
2023
Q4 		$24.3M Buy
1,666,065
+523,455
+46% +$6.35M 0.36% 102
2023
Q3 		$14M Buy
1,142,610
+336,910
+42% +$4.39M 0.22% 133
2023
Q2 		$9.62M Buy
+805,700
New +$10.5M 0.14% 147

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return

TimesSquare Capital Management's DAWN Position: Q1 2025 in Review

TimesSquare Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2025, closing a stake of 1,710,926 shares — an estimated $21.7M sold.

TimesSquare Capital Management first reported a position in DAWN in Q2 2023 and held it in 7 quarters. The position peaked at $27M in Q1 2024. 184 funds tracked by Wall St. Rank hold DAWN as of Q1 2025.

  • TimesSquare Capital Management reported no remaining Day One Biopharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • TimesSquare Capital Management sold 1,710,926 Day One Biopharmaceuticals shares in Q1 2025, an estimated $21.7M.
  • TimesSquare Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 7 quarters.
  • TimesSquare Capital Management's Day One Biopharmaceuticals position peaked at $27M in Q1 2024.
  • 184 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2025.

Based on TimesSquare Capital Management's 13F filing for Q1 2025, filed 2 May 2025.